161 related articles for article (PubMed ID: 37285223)
1. Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors.
Satish D; Lin IH; Flory J; Gerdes H; Postow MA; Faleck DM
Oncologist; 2023 Dec; 28(12):1085-1093. PubMed ID: 37285223
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.
Whitcomb DC; Bodhani A; Beckmann K; Sander-Struckmeier S; Liu S; Fuldeore M; Pollack PF; Khurmi RP
Pancreas; 2016; 45(5):679-86. PubMed ID: 26495784
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study.
Eshet Y; Baruch EN; Shapira-Frommer R; Steinberg-Silman Y; Kuznetsov T; Ben-Betzalel G; Daher S; Gluck I; Asher N; Apter S; Schachter J; Bar J; Boursi B; Markel G
Cancer Immunol Res; 2018 Dec; 6(12):1453-1458. PubMed ID: 30275274
[TBL] [Abstract][Full Text] [Related]
5. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
6. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
Whitcomb DC; Lehman GA; Vasileva G; Malecka-Panas E; Gubergrits N; Shen Y; Sander-Struckmeier S; Caras S
Am J Gastroenterol; 2010 Oct; 105(10):2276-86. PubMed ID: 20502447
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
Graff GR; McNamara J; Royall J; Caras S; Forssmann K
Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
[TBL] [Abstract][Full Text] [Related]
8. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
Townsend MJ; Liu M; Giobbie-Hurder A; Sack JS; LeBoeuf NR; Hodi FS; McNabb-Baltar J; Grover S
J Natl Compr Canc Netw; 2023 Aug; 21(8):831-840.e3. PubMed ID: 37549912
[TBL] [Abstract][Full Text] [Related]
9. A Retrospective Real-World Evidence Evaluation of the Characteristics of Exocrine Pancreatic Insufficiency in Patients With Chronic Pancreatitis and Type 2 Diabetes Treated With Pancrelipase in the United States.
Rosenberg J; Reddy MN; Seelam P; Li O; Twal J; Pack J
Pancreas; 2022 Nov-Dec 01; 51(10):1308-1314. PubMed ID: 37099771
[TBL] [Abstract][Full Text] [Related]
10. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.
Gubergrits N; Malecka-Panas E; Lehman GA; Vasileva G; Shen Y; Sander-Struckmeier S; Caras S; Whitcomb DC
Aliment Pharmacol Ther; 2011 May; 33(10):1152-61. PubMed ID: 21418260
[TBL] [Abstract][Full Text] [Related]
11. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
Kuhn RJ; Gelrud A; Munck A; Caras S
Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
[TBL] [Abstract][Full Text] [Related]
12. Exocrine pancreatic insufficiency following esophagectomy.
Huddy JR; Macharg FM; Lawn AM; Preston SR
Dis Esophagus; 2013 Aug; 26(6):594-7. PubMed ID: 23199208
[TBL] [Abstract][Full Text] [Related]
13. The effect of oral pancreatic enzyme supplementation on the course and outcome of acute pancreatitis: a randomized, double-blind parallel-group study.
Kahl S; Schütte K; Glasbrenner B; Mayerle J; Simon P; Henniges F; Sander-Struckmeier S; Lerch MM; Malfertheiner P
JOP; 2014 Mar; 15(2):165-74. PubMed ID: 24618443
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor-related Pancreatitis: A Case Series, Review of the Literature and an Expert Opinion.
Kramer S; van Hee K; Blokzijl H; van der Heide F; Visschedijk MC
J Immunother; 2023 Sep; 46(7):271-275. PubMed ID: 37216403
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
[TBL] [Abstract][Full Text] [Related]
16. Exocrine Pancreatic Insufficiency Following Acute Pancreatitis: Systematic Review and Meta-Analysis.
Huang W; de la Iglesia-García D; Baston-Rey I; Calviño-Suarez C; Lariño-Noia J; Iglesias-Garcia J; Shi N; Zhang X; Cai W; Deng L; Moore D; Singh VK; Xia Q; Windsor JA; Domínguez-Muñoz JE; Sutton R
Dig Dis Sci; 2019 Jul; 64(7):1985-2005. PubMed ID: 31161524
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis.
Toskes PP; Secci A; Thieroff-Ekerdt R;
Pancreas; 2011 Apr; 40(3):376-82. PubMed ID: 21343835
[TBL] [Abstract][Full Text] [Related]
18. Effect of Pancrelipase Therapy on Exocrine Pancreatic Insufficiency Symptoms and Coefficient of Fat Absorption Associated With Chronic Pancreatitis.
Barkin JA; Barkin JS
Pancreas; 2021 Feb; 50(2):176-182. PubMed ID: 33560089
[TBL] [Abstract][Full Text] [Related]
19. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study.
Brady MS; Garson JL; Krug SK; Kaul A; Rickard KA; Caffrey HH; Fineberg N; Balistreri WF; Stevens JC
J Am Diet Assoc; 2006 Aug; 106(8):1181-6. PubMed ID: 16863712
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Pancreatic Injury and Pancreatitis in Patients Treated With Immune Checkpoint Inhibitors.
Hori Y; Naitoh I; Naiki-Ito A; Kawai T; Yoshida M; Kato A; Kachi K; Sahashi H; Adachi A; Toyohara T; Kito Y; Yamamoto T; Takahashi S; Kataoka H
Clin Transl Gastroenterol; 2024 Apr; 15(4):e00667. PubMed ID: 38088372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
